Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Yen’s Rise, Slow New Drug Launches Cloud Astellas’ 2008 Earnings Outlook

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Having no large extra charges for acquisitions like its Japanese competitors, Astellas Pharma predicted Nov. 5 revenues and earnings for fiscal 2008 would be slightly better than its earlier forecast but the yen's appreciation and slow new drug launches would nudge the performance modestly lower than in the preceding business year

You may also be interested in...

Takeda Copes With FDA Delays, Yen Appreciation and Acquisition Drags in 2008

TOKYO - U.S. FDA has moved back its PDUFA date on yet another Takeda drug - this time dipeptidyl peptidase-4 inhibitor SYR-322 (alogliptin) - making it the third Takeda drug facing FDA delays this year, Takeda President Yasuchika Hasegawa told a Nov. 4 earnings conference

Astellas’ Telavancin Application Withdrawn In Europe, To Be Reworked With HAP Indication

Astellas has withdrawn its application to market Vibative (telavancin) for adult complicated skin and soft tissue infections in Europe, but plans to submit a new application in 2009 that includes an indication for hospital-acquired pneumonia

Astellas Tacrolimus Approval Remains At Bay

Astellas Pharma has met with another snag in its attempt to win FDA approval for the once-daily version of its immunosuppressant Prograf (tacrolimus) with receipt of an FDA "approvable" letter for prophylaxis of organ rejection in liver transplant patients

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts